Three years after the accelerated approval of its anti-amyloid Alzheimer’s therapy, Biogen—neck and neck in the market with ...

Biogen Inc.’s new at-home Alzheimer’s drug will give the company an edge over rival Eli Lilly Co.’s competing therapy, its ...

U.S. pharmaceutical company Eli Lilly is expected to disclose the top-line results (key findings from phase 3 clinical trials) of its new drug candidate ‘remternutab,’ being developed as a successor ...

This month we have a feature on Alzheimer’s disease and dementia, starting with the article on page 16 from Cindy Birck, ...

Developed in partnership with agency Wieden+Kennedy Portland, Lilly’s Good Days officially launched on Sunday. The spot will air in the final slot before showings of Wicked: For Good and during the ...

A highly anticipated Alzheimer’s medication from Eli Lilly gained the support of a federal advisory panel Monday, paving the way for it to become the second drug of its kind authorized in the United ...

At the 44th Annual JP Morgan Healthcare conference 2026, Eli Lilly highlighted lepodisiran and muvalaplin as the key drugs in ...

Lilly has launched six early-stage clinical programs, and 34 discovery programs with a focus on incretins, amylins, and novel ...

Lilly is providing up to $40 million to the university to expand access to clinical trials in Indiana. 13News spoke with David Rosenberg, president and CEO of the IU Launch Accelerator for Biosciences ...